Billerica, Mass. — Quanterix Corporation reported second-quarter 2026 revenue of $32.9 million, up 34% from $24.5 million a year earlier, but lowered its full-year revenue forecast amid commercial execution challenges and continued weakness in its end markets.
The precision biomarker company reported a GAAP gross margin of 38.5%, compared with 40.9% in the prior-year quarter. Adjusted gross margin increased to 47.9% from 41.8%.
Quanterix posted an adjusted EBITDA loss of $10 million, compared with a loss of $13.7 million a year earlier.
The company ended the quarter with $96.9 million in cash, cash equivalents, marketable securities and restricted cash. Adjusted cash usage totaled $4 million after excluding $1.7 million in integration and certain employee separation costs, down $10.8 million from the first quarter.
“We made meaningful progress in the second quarter, including strengthening our leadership team and preserving cash better than planned. However, revenue fell short of our expectations, driven by execution challenges and continued market softness,” said Everett Cunningham, President and CEO of Quanterix.
Cunningham said the company is reorganizing its commercial teams and adding senior leadership as it seeks to improve execution and operating results.
Quanterix completed the integration of its enterprise resource planning system during the quarter, marking the final stage of its Akoya acquisition integration program. The company said the program generated $85 million in annualized savings.
The company also recorded a $26.9 million goodwill impairment related to the Akoya acquisition. Quanterix said the non-cash accounting charge does not affect its operations or liquidity.
Quanterix continued to expand its diagnostics operations during the quarter, naming Jim Gute Chief Commercial Officer, Geoff Albrecht Senior Vice President and General Manager of Diagnostics, Anthony Catalano Chief Operating Officer and Jason Faessler Chief Financial Officer.
The company also reported progress in its blood-based Alzheimer’s disease testing business. Beginning July 1, Anthem Blue Cross and Blue Shield members became eligible for coverage of qualifying blood-based biomarker testing, including Quanterix’s Lucent AD Complete test, when medical necessity requirements are met.
Quanterix also presented new clinical data on Alzheimer’s testing and was selected as a Co-Investigator institution in the PD-BUILD program, part of the Aligning Science Across Parkinson’s Collaborative Research Network. The program will support development of biomarker tools for Parkinson’s disease research.
The company launched its Simoa Ultra-Sensitive Immunoassay NPTX2 and introduced two spatial-analysis products during the quarter.
Quanterix now expects 2026 revenue of $142 million to $148 million, down from its previous forecast of $169 million to $174 million. It expects adjusted gross margin of 48% to 50%, compared with its previous projection of 49% to 53%.
The company now expects to achieve cash-flow break-even in 2027 and forecasts approximately $80 million in cash at the end of 2026, down from its previous estimate of $100 million. Quanterix expects to finish the year with no debt.
